维迪西妥单抗和术后化疗用于治疗人表皮生长因子受体2阳性的局限性尿路上皮癌患者的临床疗效分析

Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma

摘要:

目的 初步探索人表皮生长因子受体2（human epidermal growth factor receptor 2，Her-2）阳性的局限性尿路上皮癌患者术后辅助使用维迪西妥单抗的效果。方法 回顾性分析32例术后辅助使用维迪西妥单抗的局限性尿路上皮癌患者（维迪西妥组）和104例术后使用传统化疗的患者（术后化疗组）临床资料，随访患者的复发情况，对比分析2组患者的复发率和不良反应率。结果 2组患者的基线数据和术前术后的相关数据没有统计学差异（P>0.05）。维迪西妥组患者术后1人复发，其复发率（9.4%）远远低于术后化疗组（20.2%）（P=0.007）。同时，维迪西妥组不良反应发生率（12.5%）低于术后化疗组（20.2%）（P=0.022）。结论 术后治疗的12个月内，维迪西妥组患者与接受传统化疗的患者相比，复发率和不良反应率相对更低，提示维迪西妥在降低尿路上皮癌患者术后复发率和延缓疾病进展方面有探究意义。

Abstract:

Objective To explore the preliminary efficacy of Disitamab Vedotin（RC48） as postoperative adjuvant therapy in patients with Her-2 positive locally advanced urothelial carcinoma.Methods The clinical data of 32 postoperative patients who received adjuvant therapy with RC48（RC48 group） and 104 postoperative patients who received conventional chemotherapy for locally advanced urothelial carcinoma（chemotherapy group） were retrospectively analyzed. The recurrence status of patients was followed up. The recurrence rate and adverse reaction rate of the two groups were compared.Results There were no significant differences in baseline data and preoperative/postoperative data between the two groups（P>0.05）. The recurrence rate（9.4%，1 case） of the RC48 group was significantly lower than that of the chemotherapy group（20.2%）（P=0.007）. The incidence of adverse reactions in the RC48 group（12.5%） was significantly lower than that in the chemotherapy group（20.2%）（P=0.022）.Conclusion Within 12 months of postoperative treatment，the recurrence rate and adverse reaction rate of patients in the RC48 group were lower than those in the conventional chemotherapy group，suggesting that RC48 has clinical significance in reducing the recurrence rate and delaying the progression of urothelial carcinoma in postoperative patients.